According to the FDA, Drug-Induced Liver Injury has been the most frequent single cause of safety-related drug marketing withdrawals for the past 50 years and is often associated with acute liver failures. DILI studies have shown latency to onset (weeks to months) and a lack of clear dose dependency. Moreover, the immunologic reaction is associated with inhibition of transporters, mitochondrial injury, endoplasmic reticulum and oxidative stress and proinflammatory cytokines that further amplify the injury mechanisms that lead to acute DILI. Modelling the system in vitro has so far been an overtly simplified method as most responses are a global average of all the hepatic cells and often pooled samples (different samples, ages and physiological status) in a well-mixed system. These study models fail to simulate unique liver flow system called as a portal triad and is responsible for dramatic variations within a liver structure. The cells closer to the central vein may express different levels of enzymes. Oxygen concentration, nutrients, and hormone concentration could also account for the heterogeneity of the system.
Our ‘Liver on-chip’ provide an integrated system for real-time evaluation to study mechanistic of drug toxicity for longer periods with hepatocytes generated from induced pluripotent stem cells and multicellular studies to understand the role of sinusoidal endothelial cell, stellate and Kupffer cells. The system is powered with wider genetic data evaluation and RNA sequencing for drug response across major drug metabolising enzymes such as Cytochrome P450s. Our ‘on the chip’ systems have all integrated simulation features for numerical analysis and data structures for studying the fluid flows. CFD evaluations are used to understand the fluid characteristics this has huge value to understand the properties of media used for in vitro studies and simulating the behaviour of fluids in the body.

Stemnovate in vitro testing platform simulates the liver response to evaluate predictable and unpredictable hepatotoxins over the breadth of the genetically diverse human population. The processes are highly data-driven with high-resolution images, genomic profiles, biological information, molecular and metabolite profiles. The machine learning can correlate, assimilate and connect the data more rapidly to help discover patterns. Our approach for deep learning will allow data exploration to identify key features and design of the cognitive network that can automate the prediction of toxicity and will be a game-changing technology for precision drug discovery.

  1. Stemnovate is capable of designing and manufacturing a bespoke fluidic component to enhance repeatability of complex cell culture
  2. As a company, we are able to quickly design, validate and manufacture prototypes and complex designs
  3. Once a methodology is optimised the process can be set for reproducibility and automation
  4. We support projects to achieve a higher standard of accuracy, evaluating biocompatibility and tolerance.

Our clients say

You are doing some amazing and important work at Stemnovate, we are happy to be associated with your project.

Volunteer for blood donation for liver research

Thank you for your presentations, they were really great and stimulating. I am very happy we met and that we could get the cells in culture!

Academic Institution
University of Bern

CASE STUDIES & Partnership

Partnering for advanced engineering and measurement standards

Stemnovate has partnered with National Physical Laboratory for advancing the biosensing technology and exploring the novel technologies for imaging of complex cellular models.

Partnering for Better Veterinary Research

Stemnovate is partnering up with the world renowned Roslin Institute on a project to create in vitro modelling systems for muscular studies that can help make new discoveries for better animal health and production.